As JAK/STAT signaling is known to play a significant role in the pathogenesis of myeloproliferative disorders and rheumatoid arthritis, the development of JAK/STAT inhibitors have recently received considerable attention as a pharmacologic intervention for these conditions [27, 28]. The gene discussed is SOAT1; the disease is myeloproliferative disorder.